CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...